thank
better
select
recipi
donor
improv
surgic
anaesthet
procedur
better
manag
immunosuppress
therapi
earli
postop
surviv
lung
transplant
recipi
ltr
improv
sinc
advent
lung
transplant
wherea
earli
death
relat
primari
graft
dysfunct
acut
reject
ar
longterm
prognosi
threaten
chronic
lung
allograft
dysfunct
clad
usual
form
bronchiol
obliteran
syndrom
bo
affect
lung
recipi
within
year
transplant
clad
repres
lead
caus
death
year
lung
transplant
infecti
respiratori
complic
also
major
caus
morbid
mortal
ltr
respons
third
death
occur
first
year
post
transplant
half
death
longterm
followup
sever
infect
result
sever
factor
includ
induc
immunosuppress
direct
exposur
graft
microorgan
final
less
effect
mucociliari
function
lymphat
drainag
cough
reflex
follow
denerv
graft
moreov
stenosi
ischem
process
occur
surgic
anastomosi
decreas
clearanc
secret
promot
colon
invas
microorgan
bacteri
infect
lead
caus
respiratori
infect
ltr
associ
occurr
clad
well
establish
mani
author
admit
viral
respiratori
tract
infect
vrti
may
associ
clad
remain
controversi
depend
definit
respiratori
infect
viru
panel
studi
time
limit
vrti
spirometr
analysi
consider
intercurr
event
possibl
influenc
respiratori
function
similarli
associ
vrti
ar
continu
debat
literatur
studi
identifi
associ
two
event
other
includ
recent
metaanalysi
found
link
howev
knowledg
impact
viralbacteri
coinfect
graft
surviv
specif
studi
compar
singl
vrti
patient
without
respiratori
infect
develop
rapid
antigen
test
molecular
biolog
techniqu
facilit
detect
diagnosi
sever
virus
new
multiplex
pcr
method
polymeras
chain
reaction
fast
sensit
andabl
detect
enlarg
number
virus
easili
detect
eg
metapneumoviru
coronaviru
bocaviru
rhinoviru
c
thu
hypothesi
impact
viral
infect
least
sever
bacteri
respiratori
infect
lung
graft
function
among
ltx
object
studi
assess
cohort
studi
occurr
late
viral
bacteri
respiratori
infect
ltr
compar
respect
impact
graft
function
without
respiratori
infect
retrospect
screen
individu
underw
lung
transplant
septemb
septemb
bichatclaud
bernard
teach
hospit
pari
franc
cohort
evalu
occurr
late
viral
bacteri
respiratori
infect
graft
function
overtim
exclus
criteria
death
first
month
transplant
avail
pulmonari
function
assess
time
document
infect
month
herpet
cytomegaloviru
pneumonia
order
includ
patient
steadi
state
studi
late
respiratori
infect
ie
censur
first
month
lung
transplant
period
postop
complic
frequent
usual
intertwin
patient
regularli
follow
routin
followup
visit
patient
symptom
record
spirometr
measur
blood
test
radiolog
explor
bronchoscop
procedur
bronchoalveolar
fluid
transbronchi
biopsi
systemat
perform
test
bacteri
viral
pathogen
accord
local
guidelin
respiratori
sampl
bronchial
aspir
bronchoalveolar
fluid
nasopharyng
sampl
review
sever
mpcr
test
use
studi
period
maastricht
netherland
septemb
februari
maastricht
netherland
march
june
filmarray
respiratori
panel
biofir
craponn
franc
use
june
septemb
chang
made
decreas
time
result
variou
test
use
report
similar
perform
confirm
intern
method
valid
similar
viral
divers
observ
time
reliabl
also
assess
throughout
studi
period
regular
qcmd
control
glasgow
uk
sampl
defin
bacteriolog
posit
bacteria
present
cfuml
sputum
cfuml
bronchial
aspir
cfuml
bronchoalveolar
fluid
accord
virolog
bacteriolog
result
respiratori
sampl
patient
divid
three
group
follow
patient
present
viral
respiratori
infect
viral
infect
group
vig
iepati
least
one
posit
virolog
respiratori
sampl
symptomat
nasopharyng
swab
test
posit
rhinoviru
consid
posit
signific
viru
ignoredpati
present
bacteri
respiratori
infect
without
respiratori
viru
bacteri
infect
group
big
ie
patient
posit
bacteriolog
sampl
treat
antibiot
without
posit
virolog
sampl
studi
period
ii
patient
bacteriolog
posit
sampl
treat
antibiot
therapi
take
samplespati
without
respiratori
infect
control
group
cg
ie
patient
virolog
bacteriolog
posit
respiratori
sampl
studi
nasopharyng
swab
posit
rhinoviru
posit
bacteriolog
respiratori
sampl
follow
antibiot
treatment
ie
consid
simpl
bacteri
carriag
date
inclus
defin
date
respiratori
sampl
interest
two
infect
group
vig
big
date
first
outpati
consult
cg
primari
endpoint
occurr
bo
month
inclus
secondari
endpoint
occurr
ar
quantit
chang
forc
expiratori
volum
month
inclus
well
death
whole
studi
period
follow
definit
use
assess
outcom
bo
defin
accord
intern
societi
heart
lung
transplant
ishlt
algorithm
base
forc
expiratori
volum
valu
bosworsen
defin
worsen
previous
defin
stage
bosar
defin
basi
transbronchi
biopsi
demonstr
least
grade
acut
reject
defin
ishlt
cellular
reject
patient
biopsi
could
perform
acut
reject
defin
deterior
lung
function
identifi
aetiolog
posit
respond
highdos
corticosteroid
delta
defin
last
inclus
quantit
variabl
present
use
median
quartil
compar
ttest
varianc
analysi
qualit
variabl
compar
use
test
fisherexact
test
outcom
compar
use
logist
regress
multivari
model
adjust
time
sinc
transplant
age
sex
sensit
analysi
carri
exclud
patient
bo
inclus
statist
analysi
done
use
r
softwar
version
studi
approv
cepro
evalu
de
protocol
de
recherch
observationnel
ethic
committe
number
cepro
septemb
septemb
patient
receiv
lung
transplant
bichat
hospit
fiftyf
patient
exclud
analysi
death
within
month
follow
transplant
six
due
lack
spirometri
assess
inclus
month
afterward
two
patholog
proven
herpet
pneumonia
among
remain
ltr
least
one
posit
virolog
respiratori
sampl
thu
patient
divid
three
group
accord
criteria
describ
vig
big
patient
monoinfect
bacteria
coinfect
patient
cg
correspond
flow
chart
present
fig
nineteen
respiratori
sampl
bronchoalveolar
lavag
bronchial
aspir
gener
characterist
type
immunosuppress
prior
viral
infect
similar
across
three
group
except
renal
dysfunct
egfr
preval
vig
tabl
previou
ar
requir
treatment
month
prior
inclus
occur
patient
vig
big
none
cg
p
among
patient
present
bo
inclus
classifi
vig
compar
big
cg
p
patient
includ
median
time
iqr
day
transplant
infect
group
display
similar
respiratori
symptom
likewis
biolog
present
infect
group
close
inflammatori
surrog
leucocyt
creactiv
protein
platelet
differ
statist
big
patient
prone
hospit
vs
p
present
sever
decreas
inclus
ml
vs
ml
compar
vig
among
patient
examin
thorac
tomodensitometri
seven
patient
present
new
infiltr
picornaviru
frequent
detect
viru
vig
n
follow
parainfluenza
viru
n
syncyti
respiratori
viru
n
tabl
pseudomona
aeruginosa
main
detect
bacteria
found
patient
big
cg
neglect
bacteria
pseudomona
aeruginosa
n
corynebacteria
striatum
n
other
n
three
patient
one
detect
viru
eight
patient
one
detect
bacteria
overal
rate
worsen
signific
differ
three
group
tabl
sixteen
patient
die
studi
period
bo
stroke
neoplasia
sever
infect
unknown
caus
signific
differ
three
group
tabl
month
observ
delta
significantli
differ
three
group
neg
delta
ml
iqr
vig
median
increas
ml
cg
ml
big
p
rate
ar
significantli
differ
three
group
vig
big
cg
overal
p
ar
occur
earlier
big
median
day
vig
day
p
multivari
analysi
trend
toward
higher
risk
vig
vs
big
adjust
p
multivari
analys
adjust
time
transplant
inclus
age
sex
associ
ar
vig
remain
signific
although
wide
confid
interv
aor
p
tabl
two
infect
group
outcom
differ
symptomat
patient
n
asymptomat
patient
n
thirteen
patient
prior
bo
inclus
cg
vig
big
trend
toward
viral
respiratori
investig
among
patient
bo
inclus
median
samplespati
patient
without
bo
inclus
p
howev
sensit
analysi
perform
remain
patient
without
bo
inclus
found
similar
result
term
signific
associ
effect
develop
new
bo
ar
tabl
way
infect
patient
significantli
investig
cg
respect
sampl
per
patient
vig
big
cg
p
studi
show
first
month
follow
transplant
half
ltr
affect
vrti
clinic
present
late
viral
andor
bacteri
infect
baselin
similar
albeit
addit
sign
sever
bacteri
infect
singl
late
vrti
strongli
impact
patient
prognosi
lead
increas
risk
ar
trend
increas
risk
bo
without
signific
associ
sever
secondari
declin
respiratori
function
compar
late
bacteri
respiratori
infect
consequ
differ
infect
similar
whether
infect
symptomat
time
viral
bacteri
detect
studi
patient
exhibit
least
one
posit
viral
respiratori
sampl
followup
rate
vari
among
studi
screen
techniqu
reason
withdraw
studi
use
cell
cultur
screen
method
report
viru
detect
rate
respiratori
sampl
around
use
molecular
biolog
test
significantli
increas
preval
decid
exclud
infect
cmv
especi
cmv
diseas
respond
differ
trigger
infect
prevent
differ
protocol
evolut
studi
period
induc
death
graft
reject
patient
group
regard
microbiolog
aetiolog
confirm
frequent
virus
detect
pcr
test
correspond
picornaviru
group
follow
parainfluenza
virus
coronavirus
alreadi
describ
worthi
note
big
picornaviru
frequent
detect
virus
coinfect
picornaviru
often
consid
contamin
controversi
clinic
impact
inde
recent
prospect
studi
demonstr
rhinovirus
frequent
ltr
even
patient
asymptomat
influenza
rare
identifi
among
lung
graft
patient
especi
compar
nonlung
graft
patient
hospit
use
mpcr
assay
vs
explain
high
vaccin
rate
specif
prevent
measur
complianc
among
lung
graft
patient
rel
among
bacteri
infect
pseudomona
aeruginosa
corynebacteria
striatum
often
detect
bacteria
known
respons
seriou
infect
ltr
alreadi
shown
symptomat
featur
initi
infect
impact
graft
surviv
suggest
patient
symptomat
natur
infect
taken
account
concern
ar
impact
late
respiratori
viral
andor
bacteri
infect
graft
function
significantli
differ
three
time
ar
within
month
vig
big
compar
cg
studi
support
associ
studi
includ
metaanalysi
find
signific
link
differ
could
explain
varieti
criteria
use
defin
ar
chose
identifi
ar
histolog
pattern
show
stage
least
inde
previou
studi
demonstr
minim
reject
associ
increas
risk
bo
develop
progress
compar
reject
top
notic
significantli
longer
delay
ar
vig
big
suggest
impact
viral
infect
lung
graft
function
must
screen
even
sever
week
especi
asymptomat
ltr
lack
specif
manag
morbid
viral
infect
could
attribut
trivial
viral
colon
lead
neglect
chronic
caus
inflamm
thu
potenti
reject
therefor
seem
import
assess
impact
respiratori
viral
infect
graft
function
emphas
prevent
viral
infect
immunocompromis
frequent
sampl
patient
includ
wide
respiratori
viru
detect
molecular
techniqu
strengthen
spirometr
control
viral
infect
allcaus
mortal
evalu
month
studi
rate
consist
studi
explain
high
rate
comorbid
among
patient
half
arteri
hypertens
diabet
mellitu
deep
immunosuppress
requir
numer
complic
lung
graft
knowledg
studi
first
allow
direct
comparison
impact
late
viral
bacteri
respiratori
infect
ltr
abl
analyz
spirometri
data
inclus
month
present
result
extens
panel
viral
pcr
test
studi
sever
limit
firstli
small
number
patient
could
restrict
power
conclus
especi
patient
classifi
nasopharyng
swab
n
aor
present
wide
rang
must
interpret
accordingli
howev
studi
remain
one
largest
avail
cohort
topic
date
despit
small
sampl
size
abl
illustr
late
vrti
strongli
impact
patient
prognosi
lead
increas
risk
ar
addit
although
signific
trend
higher
risk
occurr
outcom
bo
death
vrti
believ
find
import
lead
design
larger
studi
small
number
patient
among
group
bacteri
infect
group
bacteri
viral
infect
decid
merg
two
group
could
also
debat
howev
done
first
similar
present
patient
group
second
basi
hypothesi
bacteri
infect
respons
major
acut
part
lung
graft
malfunct
ii
group
subject
intervent
use
antibiot
secondli
retrospect
design
lead
sever
bias
indic
bia
lead
higher
infect
detect
patient
present
ar
month
prior
inclus
bo
prior
infect
frequent
followup
visit
trend
respiratori
sampl
patient
although
treatment
ar
month
prior
inclus
could
consid
biai
rate
significantli
differ
infect
group
small
number
patient
could
perform
sensit
analysi
among
patient
ar
month
prior
inclus
nevertheless
perform
sensit
analysi
address
hypothesi
indic
bia
repeat
multivari
model
without
consid
patient
bo
inclus
found
similar
result
suggest
bia
exist
alter
conclus
also
assum
surviv
bia
may
explain
despit
higher
lung
function
deterior
month
inclus
viral
infect
group
rate
bo
significantli
differ
rel
short
month
followup
period
use
studi
may
suffici
identifi
potenti
differ
progress
bo
group
inde
incid
bo
develop
month
first
infect
episod
studi
previou
studi
describ
incid
rate
fiveyear
period
conclud
viral
respiratori
infect
virusbacteria
coinfect
frequent
lung
graft
recipi
led
similar
clinic
biolog
present
bacteri
infect
strongli
diminish
initi
lung
function
led
hospit
wherea
singl
viral
respiratori
infect
seem
lead
greater
deterior
lung
function
acut
reject
bacteri
infect
